Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

11135	Companies
245233	Keywords
173268	Articles
132255	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 02/24/2025 at 11:26, 1 year 7 months ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 1 year 7 months ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
BRIEF

published on 02/20/2025 at 06:35, 1 year 7 months ago

Formycon dévoile les données cliniques du biosimilaire d'ustekinumab FYB202 au congrès de l'ECCO

Formycon AG FYB202 Biosimilaire Approbation Réglementaire Données Cliniques
PRESS RELEASE

published on 02/20/2025 at 06:30, 1 year 7 months ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab
BRIEF

published on 02/17/2025 at 09:32, 1 year 7 months ago

Formycon AG Updates on Biosimilar Projects and Strategic Adjustments

FDA Approval Biosimilars Financial Adjustments Commercial Strategy Price Discounts
BRIEF

published on 02/17/2025 at 09:32, 1 year 7 months ago

Formycon AG fait le point sur ses projets biosimilaires et ses ajustements stratégiques

Stratégie Commerciale Approbation De La FDA Biosimilaires Ajustements Financiers Réductions De Prix
PRESS RELEASE

published on 02/17/2025 at 09:27, 1 year 7 months ago

Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon AG provides updates on various biosimilar projects, including terminating phase III trial for FYB206. Conference call on Feb 17, 2025, to discuss recent developments

FDA Conference Call Formycon AG FYB206 Biosimilar Projects
BRIEF

published on 02/17/2025 at 08:10, 1 year 7 months ago

Formycon Updates on Phase III Trial and Valuation Adjustments

Formycon AG FDA Feedback Phase III Trial Commercialization Strategy Biosimilar Valuation
BRIEF

published on 02/17/2025 at 08:10, 1 year 7 months ago

Formycon fait le point sur l'essai de phase III et les ajustements de valorisation

Formycon AG Stratégie De Commercialisation Essai De Phase III Commentaires De La FDA Évaluation Des Biosimilaires
PRESS RELEASE

published on 02/17/2025 at 08:05, 1 year 7 months ago

EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts

FDA Feedback Valuation Adjustments Formycon FYB206 Price Discounts

Accesswire

Published on 10/05/2026 at 22:30, 12 hours 30 minutes ago

EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 20 hours 15 minutes ago

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 20 hours 30 minutes ago

Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 20 hours 30 minutes ago

Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 21 hours ago

Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth

View all ACCESSWIRE

EQS Group

Published on 10/06/2026 at 10:05, 54 minutes ago

Playseat® Marks over 30 Years since Founding the Racing Cockpit Category
Published on 10/06/2026 at 10:05, 54 minutes ago

Brook StarRay Wireless Controller Now Available -- Native PS5 Support Meets Xbox-Style Control
Published on 10/06/2026 at 10:05, 54 minutes ago

Cognizant Selected by SITA to Deliver AI-Led Global Finance Transformation on the Cloud
Published on 10/06/2026 at 10:01, 58 minutes ago

Aareal Bank provides €173 million in financing for high-quality PBSA portfolio in Milan
Published on 10/06/2026 at 10:00, 59 minutes ago

Ouverture du groupe de placements « SPF Immobilier Suisse » en novembre 2026

Les Echos

Published on 10/05/2026 at 22:12, 12 hours 47 minutes ago

AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 12 hours 47 minutes ago

AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 16 hours 47 minutes ago

Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 16 hours 47 minutes ago

Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 17 hours ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026

View all LES ECHOS COMFI WIRE